Gregory Deener
Vertrieb & Marketing bei Sucampo Pharma Americas LLC
Ursprung des Netzwerks ersten Grades von Gregory Deener
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN.
19
| Extinct | Pharmaceuticals: Major | 19 |
Sucampo Pharma Americas LLC
1
| Subsidiary | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Gregory Deener
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
AMPHENOL CORPORATION | Electronic Components | Director/Board Member | |
PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Sales & Marketing | |
ICOS Corp.
ICOS Corp. Pharmaceuticals: OtherHealth Technology ICOS Corp. manufactures medications to treat inflammation and other serious diseases. It focuses on the development of treatments for unmet medical conditions such as prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer, and inflammatory diseases. The company was founded in 1989 by Christopher Henney and George Rathman and is headquartered in Bothell, WA. | Pharmaceuticals: Other | General Counsel Chief Tech/Sci/R&D Officer | |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
Santarus, Inc.
Santarus, Inc. Pharmaceuticals: MajorHealth Technology Santarus, Inc. operates as a biopharmaceutical company. The company was founded on December 6, 1996 and is headquartered in Bridgewater, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Argenis Capital Advisors LLC
Argenis Capital Advisors LLC Investment ManagersFinance Argenis Capital Advisors LLC is an independent hedge fund manager headquartered in New York City. Founded in 2006, the firm provides investment advice to high net worth individual and institutional clients. | Investment Managers | Director of Research - Equity | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Oracle Partners LP | Chief Tech/Sci/R&D Officer | ||
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Masters Business Admin Undergraduate Degree | |
Oxagen Ltd.
Oxagen Ltd. Pharmaceuticals: MajorHealth Technology Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Arizona State University | College/University | Undergraduate Degree | |
University of Dayton | College/University | Undergraduate Degree | |
The University of Sheffield | College/University | Doctorate Degree | |
SUCAMPO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | President | |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member | |
Healthcare Royalty Management LLC
Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty Management LLC (Healthcare Royalty) is a private equity subsidiary of Cowen, Inc. founded in 2007 by Gregory Brown. The firm is headquartered in Stamford, Connecticut. | Investment Managers | Corporate Officer/Principal | |
AstraZeneca, Inc.
AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Biotechnology | Chief Tech/Sci/R&D Officer | |
OncoEthix SA
OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Roche Products Ltd.
Roche Products Ltd. Pharmaceuticals: MajorHealth Technology Roche Products Ltd. manufactures diagnostic, diabetes, and pharmaceutical products. The company was founded on December 14, 1908 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Abbott Point of Care, Inc.
Abbott Point of Care, Inc. Medical SpecialtiesHealth Technology Abbott Point of Care, Inc. manufactures handheld blood analysers. The company is headquartered in Princeton, NJ. | Medical Specialties | Sales & Marketing | |
Harvard Medical School | College/University | Doctorate Degree Doctorate Degree | |
Zeneca Pharmaceuticals
Zeneca Pharmaceuticals Pharmaceuticals: MajorHealth Technology Zeneca Pharmaceuticals manufactures medicines. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Rosemary Mazanet LLC | President | ||
COHERUS BIOSCIENCES, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
Atopix Therapeutics Ltd.
Atopix Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Atopix Therapeutics Ltd. develops medicines to treat atopic dermatitis and severe asthma. The firm also assess the safety and pharmacokinetic profile of its back-up molecule ATX2417 in a phase I study. The company was incorporated on October 10, 2012 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Perelman School of Medicine | College/University | Doctorate Degree | |
University of Pennsylvania Medical Center | College/University | Director/Board Member | |
Oncternal Oncology, Inc.
Oncternal Oncology, Inc. Pharmaceuticals: MajorHealth Technology Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
Artios Pharma Ltd.
Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
THE CANNABIST COMPANY HOLDINGS INC. | Pharmaceuticals: Other | Director/Board Member | |
ONCTERNAL THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Comprehensive Finance, Inc.
Comprehensive Finance, Inc. Miscellaneous Commercial ServicesCommercial Services Comprehensive Finance, Inc. manages a proprietary cloud-based platform. It provides payment solutions for healthcare providers including dentists, plastic surgeons, ophthalmologists, audiologists, and other healthcare specialists. The company was founded by Bruce B. Baird and is headquartered in Grapevine, TX. | Miscellaneous Commercial Services | Chief Executive Officer | |
Aqualung Therapeutics Corp.
Aqualung Therapeutics Corp. BiotechnologyHealth Technology Aqualung Therapeutics Corp. is an early-stage biotech company based in Tucson, AZ. The private company is focused on developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Aqualung Therapeutics is developing enamptor™, a next-gen platform comprised of a humanized enampt-neutralizing monoclonal antibody, a plasma-based biomarker panel, and a genotyping assay that identifies individuals at increased risk for ARDS death. The pipeline of alt is designed to target a range of diseases, including ARDS, ventilator- and radiation-induced lung injury, chorioamnionitis, prostate cancer, pulmonary hypertension, and both pulmonary and hepatic fibrosis (NASH), conditions each with significant unmet medical needs and with significant morbidity and mortality. Founded in 2016 by Stanley G. Miele and Joe G. N. Garcia, the company is led by Joe G. N. Garcia, who has been the CEO since incorporation. | Biotechnology | Founder | |
R Mazanet LLC | President | ||
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
St. John's College | College/University | Undergraduate Degree | |
UCL School of Pharmacy | College/University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 37 |
Vereinigtes Königreich | 12 |
Deutschland | 2 |
Bermuda | 2 |
Schweiz | 2 |
Sektoral
Health Technology | 28 |
Consumer Services | 10 |
Finance | 6 |
Commercial Services | 5 |
Electronic Technology | 2 |
Operativ
Director/Board Member | 62 |
Corporate Officer/Principal | 35 |
Chief Tech/Sci/R&D Officer | 17 |
Undergraduate Degree | 17 |
President | 11 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Gregory Deener
- Unternehmensverbindungen